FindTrial
Sign In

GnRH agonist/antagonist

DRUG3 trials

Sponsors

Northwestern University, Memorial Sloan Kettering Cancer Center, Astellas Pharma Global Development, Inc.

Conditions

Castration-Resistant Prostatic CancerHormone-Refractory Prostate CancerMetastatic Prostate CarcinomaProstate CancerRecurrent Prostate CarcinomaStage IV Prostate Cancer

Phase 1

A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
Not yet recruitingNCT07783282
Astellas Pharma Global Development, Inc.Prostate Cancer
Start: 2026-08-31End: 2027-04-30Target: 56Updated: 2026-08-24

Phase 2

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Active, not recruitingNCT03436654
Memorial Sloan Kettering Cancer CenterProstate Cancer
Start: 2018-06-21End: 2027-02-14Updated: 2026-04-27

Phase 4

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Active, not recruitingNCT03016741
Northwestern UniversityCastration-Resistant Prostatic Cancer, Hormone-Refractory Prostate Cancer, Metastatic Prostate Carcinoma +2
Start: 2017-03-31End: 2029-08-01Target: 100Updated: 2026-02-24

Related Papers

Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
Journal of Clinical Oncology2025-05-28
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.
Journal of Clinical Oncology2025-02-10
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).
Journal of Clinical Oncology2019-05-20
Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.
Journal of Clinical Oncology2019-03-014 citations